Error Reduction in Automated Gene Synthesis

减少自动化基因合成​​中的错误

• 批准号: 6738653
• 负责人: John Thomas Mulligan
• 金额: $ 14.29万
• 依托单位: BLUE HERON BIOTECHNOLOGY, INC.
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-30 至 2005-03-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6738653
• 关键词: DNA; biotechnology; genetic manipulation; nucleic acid chemical synthesis; nucleic acid sequence; reagent /indicator; synthetic nucleic acid; technology /technique development

DESCRIPTION (provided by applicant): The acquisition and manipulation of genes is at the heart of biological research. Fast, accurate gene synthesis can reduce the cost and accelerate the speed cf research by allowing scientists to focus on experiments rather than spending time "cutting and pasting'' DNA. In addition, it has the potential to enable novel approaches to generating new biological functions by providing the raw material for "directed-evolution" techniques. Currently one of the main barriers to low-cost gene synthesis is the frequent introduction of sequence errors during the course of chemical synthesis. The aim of this research is to develop and implement novel techniques that will remove sequence errors from synthetic DNA and increase the fidelity of the gone synthesis process. If successful, this project will significantly lower the cost of gene synthesis, reduce delivery times, and increase the reliability of the process. In turn, these improvements will lead to more widespread use of gene synthesis in commercial and NIH-supported research and measurable increases in research productivity. We plan to commercialize the process through our existing gene synthesis business. Error reduction technology will allow shorter delivery time and lower costs for gene synthesis and enable the production of high quality libraries of gone variants. In addition, a number of the technologies we generate may lead to new products for mutation detection, for the production of very high quality oligonucleotides or for high fidelity PCR cloning.

描述（由申请人提供）： 基因的获取和操纵是生物学研究的核心。快速、准确的基因合成可以降低成本，加快研究速度，让科学家专注于实验，而不是花时间“切割和粘贴”DNA。此外，它有可能通过提供“定向进化”技术的原材料，使新的方法产生新的生物功能。目前，低成本基因合成的主要障碍之一是在化学合成过程中频繁引入序列错误。这项研究的目的是开发和实施新的技术，从合成DNA中去除序列错误，并提高合成过程的保真度。如果成功，该项目将大大降低基因合成的成本，减少交付时间，并提高该过程的可靠性。反过来，这些改进将导致基因合成在商业和NIH支持的研究中得到更广泛的应用，并显著提高研究生产力。我们计划通过我们现有的基因合成业务将这一过程商业化。错误减少技术将允许更短的交付时间和更低的基因合成成本，并能够生产高质量的基因变异库。此外，我们开发的许多技术可能会产生用于突变检测、生产高质量寡核苷酸或高保真PCR克隆的新产品。